Skip to content
AnalystLens

BOSTON SCIENTIFIC CORP 8-K Report, Financial Results (Feb 4, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 4, 2026
Period End
February 4, 2026
Security
BSX
In the record · 2016–202610-K1310-Q328-K181

BSX filed 13 annual reports (10-K), 32 quarterly reports (10-Q) and 181 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Feb ’17Feb ’17
  2. Material agreement8-K · Feb ’19Feb ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Leadership change8-K · Apr ’25Apr ’25

01—Abstract

Summary

Summary of the 8-K filed February 4, 2026. Cited figures are marked; the original filing is the authoritative source.

Boston Scientific reported a strong close to 2025.

Q4 net sales were $5.286 billiona, up 15.9% reported, 14.3% operational and 12.7% organic, beating the company's guidance ranges of 14.5–16.5% reported and 11–13% organic. Cardiovascular was the main engine at 16.1% organic growth, while MedSurg grew 6.5% organic. GAAP EPS was $0.45 versus $0.38 a year ago, and adjusted EPS was $0.80 versus $0.70, above the $0.77–$0.79 guidance.

For full year 2025, net sales reached $20.074 billionb (15.8% organic growth) and adjusted EPS was $3.06, up from $2.51. GAAP diluted EPS was $1.94, up from $1.25. Quality of earnings deserves attention.

Q4 GAAP results absorbed a $194 millionc litigation-related charge, and 2025 included restructuring charges tied to discontinuing the ACURATE neo2 and ACURATE Prime aortic valves, which had roughly $50 million per quarter of prior-year global sales. The gap between GAAP and adjusted EPS remains wide because of amortization and recurring 'non-GAAP' adjustments, so investors should weigh both measures. Full-year 2025 also benefited from a $229 million acquisition-related other income item in the non-GAAP reconciliation, and 'Other, net' was positive for the year despite a negative Q4.

Looking ahead, management guided full-year 2026 reported net sales growth of 10.5–11.5% (10.0–11.0% organic) and adjusted EPS of $3.43d–$3.49. First-quarter 2026 guidance calls for 10.5–12.0% reported growth (8.5–10.0% organic) and adjusted EPS of $0.78–$0.80.

The company also disclosed pending acquisitions of Penumbra and Valencia Technologies and the completed purchase of Nalu Medical. Guidance implies deceleration from 2025's 15.8% organic pace, which investors will likely probe on the earnings call.

02—Key points

Key Highlights

  1. Q4 2025 net sales of $5.286B grew 15.9% reported and 12.7% organic, ahead of the 11–13% organic guidance range.
  2. Q4 adjusted EPS of $0.80 beat the $0.77–$0.79 guidance range; GAAP EPS was $0.45, versus $0.38 a year earlier.
  3. Full-year 2025 net sales of $20.074B grew 15.8% organic; Cardiovascular grew 20.8% organic while MedSurg grew 6.7%.
  4. Q4 GAAP results included a $194M litigation-related net charge, which was excluded from adjusted EPS.
  5. 2026 guidance: 10.0–11.0% organic net sales growth and adjusted EPS of $3.43–$3.49, implying deceleration from 2025.
  6. Pending acquisition of Penumbra (NYSE: PEN) and agreement to acquire Valencia Technologies; Nalu Medical acquisition completed.
  7. Discontinued worldwide sales of ACURATE neo2 and ACURATE Prime aortic valves in Q2 2025, which had about $50M in quarterly global sales.

03—Questions

Frequently Asked Questions

  1. Did Boston Scientific beat its Q4 2025 guidance?

    Yes. Reported net sales growth of 15.9% exceeded the 14.5–16.5% guidance range, organic growth of 12.7% exceeded the 11–13% range, and adjusted EPS of $0.80 beat the $0.77–$0.79 range. GAAP EPS of $0.45 fell short of the $0.48–$0.52 guidance range, mainly because of the litigation and restructuring charges.

  2. What is driving the 2026 growth outlook?

    The company guides to 10.0–11.0% organic and 10.5–11.5% reported net sales growth for 2026, and to $3.43–$3.49 adjusted EPS. The filing does not break out the drivers. Cardiovascular, which grew 16.1% organic in Q4, and new launches such as FARAPOINT and SEISMIQ are the likely contributors, while the lower 2026 growth rate reflects a tougher comparison base and the ACURATE exit.

  3. What was the $194 million litigation charge in Q4?

    The filing records a $194 million litigation-related net charge in operating expenses for Q4 2025 and excludes it from adjusted EPS, which reduced GAAP EPS by about $0.10. The release does not describe the underlying matter, so investors should check the Form 10-K or 10-Q for details.

  4. How significant are the pending acquisitions?

    The filing says the Penumbra acquisition and the Valencia Technologies acquisition are subject to customary closing conditions, and it does not disclose purchase prices or expected closing dates. The 2026 guidance includes no acquisition contribution from these deals, so they are not reflected in the outlook.

04—Continue

← View all 8-K filings